Evidence map›Paper›PMID 35212828›Full record

ArticleInternational journal of clinical oncology2022

Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy.

Akiko Abe, Masao Yuasa, Yoshie Imai, Tomohiro Kagawa, Ayuka Mineda, Masato Nishimura, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Using maximum plasma concentration (CCancer chemotherapy and pharmacology · 2024
    Review
  6. Article
  7. Body Weight Is a Valid Predictor of the Long-Term Prognosis of Cervical Cancer.Computational and mathematical methods in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Akiko AbeDepartment of Gynecology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. akiko06090111akiko@gmail.com.ORCID http://orcid.org/0000-0002-0241-1319
Masao YuasaDepartment of Radiology, Tokushima University Hospital, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Yoshie ImaiDepartment of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Tomohiro KagawaDepartment of Obstetrics and Gynecology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Ayuka MinedaDepartment of Obstetrics and Gynecology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Masato NishimuraDepartment of Obstetrics and Gynecology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Chisato TonoisoDepartment of Radiology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Akiko KuboDepartment of Radiology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Takashi KawanakaDepartment of Radiology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Hitoshi IkushimaDepartment of Therapeutic Radiology, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Takeshi IwasaDepartment of Obstetrics and Gynecology, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
Tokushima University · JPThe Cancer Institute Hospital · JPTokushima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes.

methodsThis retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated.

resultsThe patients' median age was 60 (range 33‒80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m

conclusionsOur findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesSarcopeniaUterine Cervical NeoplasmsAdultAgedAged, 80 and overChemoradiotherapyFemaleHumansMiddle AgedMuscle, SkeletalPrognosisRetrospective StudiesThinnessPapillomavirus VaccinesCervical cancerConcurrent chemoradiotherapyIntramuscular adipose tissue contentPrognosisSarcopeniaSkeletal muscle index

Identifiers

PMID35212828
OpenAlexW4214625583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.